연구성과로 돌아가기
2023 연구자 정보 (56 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Choi, Chel Hun (Choi, CH) |
Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea |
AAS-3301-2021 Choi, Youn |
|
[JCR상위 1.7] Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6) [JCR상위 7.7] Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICR: a phase III, randomized controlled clinical trial (KGOG1047; Debulk trial) |
SCIE | 1.7 |
ONCOLOGY OBSTETRICS & GYNECOLOGY;ONCOLOGY |
|||
|
Christianson, Dawn R. (Christianson, DR) |
Arrowhead Pharmaceut Inc, Pasadena, CA USA |
|
|
[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | mfyuen@hku.hk; | ||
|
Chung, Hyun Cheol Cheol (Chung, HCC) |
AFB-8969-2022 Chung, Hyun Cheol |
|
[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Chung, Il-Young (Chung, IY) |
|
|
[JCR상위 1.7] Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Chung, Liam Il-Young (Chung, LIY) |
제1저자 |
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60208 USA Northwestern Univ, Feinberg Sch Med, Chicago, IL USA Northwestern Mem Hosp, Dept Internal Med, Chicago, IL 60611 USA |
IQU-0821-2023 Chung, Liam Il-Young |
|
[JCR상위 1.7] Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation. [JCR상위 67.0] Survival Outcomes After Double-Lung Transplantation for Refractory Lung-Limited Cancers and Incidence of Post-Transplant Lung Cancer [JCR상위 21.0] Current and future role of double-lung transplantation for bilateral lung cancer [JCR상위 19.0] A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation [JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) |
SCIE | 1.7 |
ONCOLOGY SURGERY;TRANSPLANTATION IMMUNOLOGY;TRANSPLANTATION |
ankit.bharat@nm.org;ychae@nm.org; ankit.bharat@nm.org;YCHAE@nm.org; ychae@nm.org; |
|
|
Cloutier, Daniel (Cloutier, D) |
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med,Sch Med, Daegu, South Korea |
|
|
[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | mfyuen@hku.hk; | ||
|
Cooney, Julian P. (Cooney, JP) |
Fiona Stanley Hosp, Murdoch, Australia Univ Western Australia, Crawley, Australia |
|
|
[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study | SCIE | 1.7 | ONCOLOGY | dmiklos@stanford.edu; | ||
|
Corson, Stephen (Corson, S) |
PHASTAR, Glasgow, Lanark, Scotland |
|
|
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | robert.c.elston@gsk.com; | ||
|
Costin, Dan (Costin, D) |
|
|
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Culm, Kerry (Culm, K) |
|
|
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Cusi, Kenneth (Cusi, K) |
Univ Florida, Gainesville, FL USA |
ADV-2401-2022 Cusi, Kenneth |
|
[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | mfyuen@hku.hk; | ||
|
De Toni, Enrico N. (De Toni, EN) |
C-6496-2008 De Toni, Enrico |
|
[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | SCIE | 1.7 | ONCOLOGY | ||||
|
Djunadi, Trie Arni (Djunadi, TA) |
|
|
[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) | SCIE | 1.7 | ONCOLOGY | ||||
|
Dong, Jie (Dong, J) |
GSK, Shanghai, Peoples R China |
|
|
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | robert.c.elston@gsk.com; | ||
|
Feng, Wenqin (Feng, WQ) |
|
|
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 | SCIE | 1.7 | ONCOLOGY |
페이지 이동: